New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Array Biopharma Inc (NASDAQ:ARRY), Opexa Therapeutics Inc (NASDAQ:OPXA), Cell Therapeutics Inc (NASDAQ:CTIC), ReneSola Ltd. (ADR) (NYSE:SOL)
Array Biopharma Inc (NASDAQ:ARRY) the stock decreased -1.67% and finished the session at $4.71. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 1.73 million shares. The beta of the stock remained 1.61. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company’s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
Will ARRY Get Buyers Even After The Recent Rally? Find Out Here
Opexa Therapeutics Inc (NASDAQ:OPXA) the stock opened the session at $1.71 but then moved to $1.90. At that price, the stock showed a positive performance of 11.11%. Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company’s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).
Will OPXA Continue To Move Higher? Find Out Here
Cell Therapeutics Inc (NASDAQ:CTIC) opened the session at $1.89 and closed the session at $1.90. The stock showed a positive performance of 1.60% in previous trading session. Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL),
For How Long CTIC will fight for Profitability? Read This Trend Analysis report
ReneSola Ltd. (ADR) (NYSE:SOL) the stock advanced 1.86% and finished the session at $3.28. Traded with volume of 1.42 million shares in the prior session and the average volume of the stock remained 3.88 million shares. The beta of the stock remained 3.19. ReneSola Ltd (ReneSola), incorporated on March 17, 2006, is a global manufacturer of solar wafers and producer of solar power products based in the People's Republic of China. ReneSola possess a global network of suppliers and customers that includes some of the global manufacturers of solar cells and modules. As of December 31, 2012, the Company had an annual wafer manufacturing capacity of approximately 2,000 megawatts, consisting of monocrystalline wafer manufacturing capacity of approximately 400 megawatts and multicrystalline wafer manufacturing capacity of approximately 1,800 megawatts.
Will SOL Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)